In case of advanced breast cancer, a trial to introduce the combination of Azacitidine and entinostat drugs has been initiated (#NCT01349959) wherein Azacitidine is a cytidine analog whereas entinostat is an HDAC inhibitor [187]. The gene discussed is HDAC9; the disease is breast carcinoma.